vs
Aptorum Group Ltd（APM）与Mirion Technologies, Inc.（MIR）财务数据对比。点击上方公司名可切换其他公司
Mirion Technologies, Inc.的季度营收约是Aptorum Group Ltd的626.4倍（$277.4M vs $442.8K）。Mirion Technologies, Inc.净利率更高（6.2% vs -63.8%，领先70.0%）
Aptorum Group Ltd是一家跨国生物制药企业，专注于传染病、女性健康相关疾病和罕见病领域的创新治疗及诊断方案的研发、生产与商业化，核心运营市场覆盖北美及亚太多个国家和地区。
Mirion Technologies是全球领先的辐射检测、监测与安全解决方案提供商，核心产品涵盖个人剂量测量系统、辐射成像设备及辐射风险管理软件，服务核电、医疗、国防、工业等多个核心领域，客户遍布北美、欧洲及亚太地区。
APM vs MIR — 直观对比
营收规模更大
MIR
是对方的626.4倍
$442.8K
净利率更高
MIR
高出70.0%
-63.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $442.8K | $277.4M |
| 净利润 | $-282.5K | $17.3M |
| 毛利率 | — | 48.8% |
| 营业利润率 | -52.6% | 9.2% |
| 净利率 | -63.8% | 6.2% |
| 营收同比 | — | 9.1% |
| 净利润同比 | — | 15.3% |
| 每股收益（稀释后） | $-0.04 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APMMIR
| Q4 25 | $442.8K | $277.4M | ||
| Q3 25 | $208.8K | $223.1M | ||
| Q2 25 | — | $222.9M | ||
| Q1 25 | — | $202.0M | ||
| Q4 24 | — | $254.3M | ||
| Q3 24 | — | $206.8M | ||
| Q2 24 | — | $207.1M | ||
| Q1 24 | — | $192.6M |
净利润APMMIR
| Q4 25 | $-282.5K | $17.3M | ||
| Q3 25 | $-614.0K | $2.9M | ||
| Q2 25 | — | $8.3M | ||
| Q1 25 | — | $300.0K | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $-13.6M | ||
| Q2 24 | — | $-11.7M | ||
| Q1 24 | — | $-25.8M |
毛利率APMMIR
| Q4 25 | — | 48.8% | ||
| Q3 25 | — | 46.8% | ||
| Q2 25 | — | 46.0% | ||
| Q1 25 | — | 47.6% | ||
| Q4 24 | — | 48.1% | ||
| Q3 24 | — | 44.9% | ||
| Q2 24 | — | 47.0% | ||
| Q1 24 | — | 45.2% |
营业利润率APMMIR
| Q4 25 | -52.6% | 9.2% | ||
| Q3 25 | -71.9% | 3.3% | ||
| Q2 25 | — | 4.4% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | -0.8% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | -2.5% |
净利率APMMIR
| Q4 25 | -63.8% | 6.2% | ||
| Q3 25 | -294.0% | 1.3% | ||
| Q2 25 | — | 3.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | -6.6% | ||
| Q2 24 | — | -5.6% | ||
| Q1 24 | — | -13.4% |
每股收益（稀释后）APMMIR
| Q4 25 | $-0.04 | $0.07 | ||
| Q3 25 | $-0.09 | $0.01 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | — | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $412.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $23.1M | $1.9B |
| 总资产 | $18.7M | $3.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APMMIR
| Q4 25 | $3.5M | $412.3M | ||
| Q3 25 | $56.8K | $933.2M | ||
| Q2 25 | — | $262.6M | ||
| Q1 25 | — | $185.8M | ||
| Q4 24 | — | $175.2M | ||
| Q3 24 | — | $133.3M | ||
| Q2 24 | — | $122.2M | ||
| Q1 24 | — | $120.2M |
总债务APMMIR
| Q4 25 | — | — | ||
| Q3 25 | — | $444.8M | ||
| Q2 25 | — | $444.9M | ||
| Q1 25 | — | $686.6M | ||
| Q4 24 | — | $686.4M | ||
| Q3 24 | — | $685.1M | ||
| Q2 24 | — | $684.1M | ||
| Q1 24 | — | $685.5M |
股东权益APMMIR
| Q4 25 | $23.1M | $1.9B | ||
| Q3 25 | $22.5M | $1.8B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
总资产APMMIR
| Q4 25 | $18.7M | $3.6B | ||
| Q3 25 | $17.6M | $3.5B | ||
| Q2 25 | — | $2.7B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.6B |
负债/权益比APMMIR
| Q4 25 | — | — | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-145.9K | $73.0M |
| 自由现金流经营现金流 - 资本支出 | — | $63.2M |
| 自由现金流率自由现金流/营收 | — | 22.8% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | 4.22× |
| 过去12个月自由现金流最近4个季度 | — | $106.9M |
8季度趋势，按日历期对齐
经营现金流APMMIR
| Q4 25 | $-145.9K | $73.0M | ||
| Q3 25 | $-484.3K | $22.3M | ||
| Q2 25 | — | $12.4M | ||
| Q1 25 | — | $35.6M | ||
| Q4 24 | — | $60.8M | ||
| Q3 24 | — | $17.1M | ||
| Q2 24 | — | $15.2M | ||
| Q1 24 | — | $6.0M |
自由现金流APMMIR
| Q4 25 | — | $63.2M | ||
| Q3 25 | — | $13.0M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $27.1M | ||
| Q4 24 | — | $49.1M | ||
| Q3 24 | — | $3.9M | ||
| Q2 24 | — | $4.1M | ||
| Q1 24 | — | $-6.8M |
自由现金流率APMMIR
| Q4 25 | — | 22.8% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 13.4% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | -3.5% |
资本支出强度APMMIR
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 4.6% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.4% | ||
| Q1 24 | — | 6.6% |
现金转化率APMMIR
| Q4 25 | — | 4.22× | ||
| Q3 25 | — | 7.69× | ||
| Q2 25 | — | 1.49× | ||
| Q1 25 | — | 118.67× | ||
| Q4 24 | — | 4.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APM
暂无分部数据
MIR
| Transferred Over Time | $96.6M | 35% |
| Services | $65.0M | 23% |
| Cancer Care | $61.8M | 22% |
| Labs And Research | $34.0M | 12% |
| Other Care | $20.7M | 7% |
